Requirement for p85α regulatory subunit of class IA PI3K in myeloproliferative disease driven by an activation loop mutant of KIT

Experimental Hematology

Volumn 36, Issue 3, 2008, Pages 301-308

  Munugalavadla, Veerendra ^a   Sims, Emily C ^a   Chan, Rebecca J ^a   Lenz, Stephen D ^b   Kapur, Reuben ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

P85 ALPHA PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE IALPHA; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; STEM CELL FACTOR RECEPTOR;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL LINE; CELL TRANSFORMATION; CELL TRANSPLANTATION; CONTROLLED STUDY; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; DISEASE MODEL; ENZYMOLOGY; FLOW CYTOMETRY; GENETICS; LIVER; LUNG; METABOLISM; MOUSE MUTANT; MUTATION; PATHOLOGY; SPLEEN;

MURINAE; MUS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; LEUKEMIA, MYELOID, ACUTE; LIVER; LUNG; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; MYELOPROLIFERATIVE DISORDERS; PROTO-ONCOGENE PROTEINS C-KIT; SPLEEN;

EID: 39149093030     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.11.008     Document Type: Article

References (31)

1. Hirota S., Isozaki K., Moriyama Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
2. Longley B.J., Tyrrell L., Lu S.Z., et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 12 (1996) 312-314
3. Beghini A., Peterlongo P., Ripamonti C.B., et al. C-kit mutations in core binding factor leukemias. Blood 95 (2000) 726-727
4. Tian Q., Frierson Jr. H.F., Krystal G.W., and Moskaluk C.A. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 154 (1999) 1643-1647
5. Nagata H., Worobec A.S., Oh C.K., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 92 (1995) 10560-10564
6. Feger F., Ribadeau Dumas A., Leriche L., Valent P., and Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 127 (2002) 110-114
7. Care R.S., Valk P.J., Goodeve A.C., et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 121 (2003) 775-777
8. Nanri T., Matsuno N., Kawakita T., Mitsuya H., and Asou B. Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation. Leukemia 19 (2005) 1673-1675
9. Schnittger S., Kohl T.M., Haferlach T., et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 107 (2006) 1791-1799
10. Cairoli R., Beghini A., Grillo G., et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 107 (2006) 3463-3468
11. Shimada A., Taki T., Tabuchi K., et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 107 (2006) 1806-1809
12. Akin C., Brockow K., D'Ambrosio C., et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 31 (2003) 686-692
13. Pardanani A., Elliott M., Reeder T., et al. Imatinib for systemic mast-cell disease. Lancet 362 (2003) 535-536
14. Ma Y., Zeng S., Metcalfe D.D., et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99 (2002) 1741-1744
15. Piao X., Paulson R., van der Geer P., Pawson T., and Bernstein A. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc Natl Acad Sci U S A 93 (1996) 14665-14669
16. Ning Z.Q., Li J., and Arceci R.J. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood 97 (2001) 3559-3567
17. Ning Z.Q., Li J., McGuinness M., and Arceci R.J. STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity. Oncogene 20 (2001) 4528-4536
18. Chian R., Young S., Danilkovitch-Miagkova A., et al. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood 98 (2001) 1365-1373
19. Shivakrupa R., Bernstein A., Watring N., and Linnekin D. Phosphatidylinositol 3 kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Res 63 (2003) 4412-4419
20. Hashimoto K., Matsumura I., Tsujimura T., et al. Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation. Blood 101 (2003) 1094-1102
21. Kosmider O., Denis N., Lacout C., Vainchenker W., Dubreuil P., and Moreau-Gachelin F. Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice. Cancer Cell 8 (2005) 467-478
22. Wymann M.P., Zvelebil M., and Laffargue M. Phosphoinositide 3-kinase signalling-which way to target?. Trends Pharmacol Sci 24 (2003) 366-376
23. Geering B., Cutillas P.R., Nock G., Gharbi S.I., and Vanhaesebroeck B. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A 104 (2007) 7809-7814
24. Samuels Y., Wang Z., Bardelli A., Silliman N., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
25. Bader A.G., Kang S., Zhao L., and Vogt P.K. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5 (2005) 921-929
26. Terauchi Y., Tsuji Y., Satoh S., et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet 21 (1999) 230-235
27. Williams D.A., Tao W., Yang F., et al. Dominant negative mutation of the hematopoietic-specific Rho GTPase, Rac2, is associated with a human phagocyte immunodeficiency. Blood 96 (2000) 1646-1654
28. Munugalavadla V., Sims E.C., Borneo J., Chan R.J., and Kapur R. Genetic and pharmacologic evidence implicating the p85{α}, but not p85{β}, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis. Blood 110 (2007) 1612-1620
29. Kitayama H., Tsujimura T., Matsumura I., et al. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood 88 (1996) 995-1004
30. Xiang Z., Kreisel F., Cain J., Colson A., and Tomasson M.H. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol 27 (2007) 267-282
31. Niv M.Y., Rubin H., Cohen J., et al. Sequence-based design of kinase inhibitors applicable for therapeutics and target identification. J Biol Chem 279 (2004) 1242-1255